Purpose: Palliative gastrectomy and chemotherapy are important options for peritoneal seeding of gastric cancer. The treatment stage IV gastric cancer patient who respond to induction chemotherapy, is converted to gastrectomy (conversion therapy or conversion surgery). This study explored the clinical outcomes of gastric cancer patients with peritoneal seeding who had undergone conversion therapy. Materials and Methods: Between 2003 and 2012, gastric cancer patients with peritoneal seeding, as determined by preoperative or intraoperative diagnosis were reviewed retrospectively. Clinicopathologic characteristics and clinical outcomes of patients with peritoneal seeding were analyzed. Results: Forty-three patients were enrolled. Eighteen patients had undergone conversion surgery and 25 patients continued conventional chemotherapy. Among the 18 conversion patients, 10 received clinically curative resection. The median follow-up period was 28.5 months (range 8 to 60 months) and the total 3-year survival rate was 16.3%. The median survival time of the patients who received clinically curative conversion therapy was 37 months, and the 3-year survival rate was 50%. The median follow-up for non-curative gastrectomy patients was 18 months. No patient treated using chemotherapy survived to 3 years; the median survival time was 8 months. The differences in survival time between the groups was statistically significant (P<0.001). Conclusions: In terms of survival benefits for gastric cancer patients with peritoneal seeding, clinically curative conversion therapy resulted in better clinical outcomes.
Introduction
The prevalence of early-stage gastric cancer has been increasing as the popularity of esophagogastroduodenoscopy increases. Various early stage treatments are available depending on the nature of disease progression. When gastric cancer continues to progress or recurs, peritoneal seeding is commonly observed during the pathological course, which can lessen treatment efficacy and portend a poor prognosis.
The survival time of gastric cancer patients with peritoneal seeding is reported to be 3 to 9 months. [1] [2] [3] Management options, including systematic chemotherapy, peritonectomy, intra-peritoneal chemotherapy, and hyperthermic intraperitoneal chemotherapy have been used to improve the prognosis of patients with advanced gastric cancer and peritoneal seeding. None of these options have proven satisfactory. 4, 5 Palliative gastrectomy in advanced gastric cancer patients can reduce bleeding, perforation, and obstruction.
The treatment strategy of stage IV gastric cancer patients who respond to induction chemotherapy is converted to gastrectomy (conversion therapy or conversion surgery). This conversion is made with a curative intent, in contrast to that in palliative surgery.
Patients with stage IV advanced gastric cancer who undergo conversion surgery have good prognoses, with R0 resection predicting longer survival. 6 Conversion Surgery in Gastric Cancer
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The present study explored the clinical outcomes of conversion therapy in gastric cancer patients with peritoneal seeding.
Materials and Methods
In 
Results
Of the 43 chemotherapy patients, 18 underwent gastrectomy (conversion therapy group) and 25 did not (chemotherapy group).
The latter group of patients did not show any signs of improvement and did not subsequently undergo gastrectomy. Instead, chemotherapy was continued. The conversion therapy group showed improvement and gastrectomy was performed 2 to 12 months (average, 5.6 months) after chemotherapy initiation.
The group of 18 patients who had undergone gastrectomy had an equal number of men and women (age range 32 to 72 years;
average age, 52.8±13.7 years). Of the 10 patients who underwent clinically curative gastrectomy, four underwent subtotal gastrectomy and six underwent total gastrectomy. The total gastrectomy cases included three of extended total gastrectomy (combined organ resections). In the eight patients in the non-curative gastrectomy group, the gastrectomy type included one subtotal gastrectomy and seven total gastrectomies, with the latter including four cases of extended total gastrectomy. The combined resected organs were the spleen, distal pancreas, transverse colon, and salpinx. The mean tumor size was 7.1±4.6 cm. In both groups, the most common histologic type poorly differentiated tumors. Most of the tumors were located in the middle area of the stomach. According to the current TNM staging criteria of the American Joint Committee on Cancer, stage IB was found in two patients (11.1%), IIA in two patients (11.1%), IIIA in three patients (16.7%), IIIB in two patients (11.1%), IIIC in one patient (5.6%), and IV in eight patients (44.4%) ( Table 1) .
Two cases of intra-abdominal abscess and several cases of minor complications were treated with conservative care. There was no operation-related mortality.
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The median follow-up period was 28.5 months (range 8 to 60 months), and the total 3-year survival rate was 16.3%. The median survival time after the clinically curative conversion therapy patients was 37 months, the 2-year survival rate was 60%, and the 3-year survival rate was 50%. The median survival time, 2-year survival rate, and 3-year survival rate of the non-curative resected patients were 18 months, 37.5%, and 0%, respectively. No patient who received chemotherapy survived to 2 or 3 years, and the median survival time was 8 months. The differences between the groups were significant (P＜0.001; Fig. 1 ).
Discussion
In recent years, although the number of early-stage gastric cancer patients is increasing, advanced cases are still detected. With peritoneal seeding, the prognosis can be poor.
Because of the poor prognosis, standard conventional chemotherapy is preferable. Intra-peritoneal chemotherapy with systemic intravenous chemotherapy, intra-peritoneal heat therapy with cytoreductive surgery, active peritonectomy, induction chemotherapy, and adjuvant chemotherapy have been recently found to improve the prognosis. [9] [10] [11] [12] Performing gastrectomy in patients with gastric cancer and peritoneal seeding has reported to increase response to chemotherapy and subsequently, improves patient prognosis. 9, 13, 14 The present study compared the clinicopathologic characteristics and prognosis of patients according to gastrectomy after conventional chemotherapy (conversion therapy) and showed that clinically curative conversion therapy resulted in the best survival rate and prognosis, and that patients who underwent non-curative resected showed better outcomes than those who had continued Values are presented as number. *According to the current TNM staging criteria of the American Joint Committee on Cancer.
chemotherapy.
Laparoscopic staging was very useful for detecting peritoneal seeding, as well as for precisely ascertaining the level of peritoneal seeding without the need for laparotomy. The accuracy of noninvasive diagnosis prior to surgery is 58% to 63%, 15 and The sensitivity of laparoscopic exploration is greater than 90%. 16 Accordingly, we conducted laparoscopic staging before laparotomy in patients with high serum tumor marker levels or who had clinical T4a and T4b preoperatively. We detected peritoneal seeding in nearly 40% of these patients.
The total 3-year survival rate was 16.3% in this study, which is better than those previously reported of approximately 15% 17 and 18%. 18 In the present study, the 3-year survival rate of patients who had clinically curative conversion therapy was 50%. The rates exceeded 50% in one report 17 and was only 12% in another. 19 The present finding of a 0% 3-year survival rate in patients who continued alternative chemotherapy is in line with the result of a prior report. 19 Despite differences in patients and research and treatment methods, present and previously reported survival rates are similar.
Continued chemotherapy was not useful in increasing survival in peritoneal seeding patients, but successful conversion therapy was.
A previous study indicated that radical curability can be achieved using gastrectomy and that metastasis can be cured when the peritoneal seeding stage is P1. 20 Improved prognosis also can be expected with gastrectomy when the peritoneal seeding is not more severe than P2. 21 Induction chemotherapy in 61 patients with P3 required additional gastrectomy. 17 Removal of the primary tumor may reduce the obstruction, bleeding, perforation, and ascites caused by the primary tumor and increase patient comfort. 22 In the present study, the median survival time of patients who underwent non-curative resection was 18 months, and the 2-year survival rate was 37.5%. However, patients who continued chemotherapy did not survive to 2 years, and the median survival time Although it is difficult to generalize the results of this study, performing gastrectomy actively when feasible is considered beneficial. To improve the prognoses of gastric cancer patients with peritoneal seeding, it is important to actively consider gastrectomy, depending on the response to induction chemotherapy. Palliative gastrectomy was also effective in improving survival. It will be necessary to compare the efficacy of continued chemotherapy and palliative gastrectomy in a well-designed, prospective, randomized clinical study to enable treatment guidance of gastric cancer patients with peritoneal seeding.
